A biotech developing targeted oral cancer pills, currently testing two kinase inhibitors in early-stage trials for leukemia and HER2-positive tumors.
No revenue yet; the company burns cash, with net losses of USD -0.10B in 2025 and USD -0.09B in 2024, funded by investors.
Potential edge from novel drug designs, but no approved product or proven efficacy yet; competitors like Novartis and Pfizer dominate kinase inhibitor space, making any moat unproven and weak.
Key events, in time order
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
